Peregrine Pharmaceuticals Receives FDA Approval for its Cotara(TM) Phase III Registration Trial Design for Brain Cancer

Peregrine Pharmaceuticals Receives Additional 180-Day Grace Period from Nasdaq

Peregrine's Anti-Angiogenesis Antibody, 2C3, Shown to Inhibit Tumor Growth by 75%

Peregrine Pharmaceuticals Reduces Clinical Department

Peregrine To Develop Vascular Targeting Agents (VTA) With Schering AG

Peregrine Announces Quarterly Conference Call

Peregrine's Non-Radiolabeled Lym-1 Antibody Shows Significant Anti-Tumor Effect on B-Cell Lymphoma in Preclinical Studies

Peregrine's Phosphatidylserine-Based Vascular Targeting Agent Technology Published In International Journal of Radiation - Oncology - Biology - Physics

Peregrine Pharmaceuticals Receives Orphan Drug Designation For Cotara(TM) In Europe

Avid Bioservices Presents at IBC Biopharmaceutical Production Week Conference